Interpace Biosciences Announces Reverse Split to Support Nasdaq Uplisting
IDXG sits 84% above its 52-week low of $0.77.
Summary
Interpace Biosciences announced a reverse stock split to support its proposed Nasdaq uplisting. The move follows shareholder approval of the reverse split at the 2026 annual meeting, as disclosed in the 8-K filed August 20. The company returned to profitability in Q2 2026 with net income of $0.16 million, and the uplisting could improve liquidity and institutional access. The reverse split ratio and effective date were not disclosed.
At the time of this announcement, IDXG was trading at $1.42 on OTC in the Life Sciences sector, with a market capitalization of approximately $39.3M. The 52-week trading range was $0.77 to $2.40. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.